Tafasitamab
- Generic Name
- Tafasitamab
- Brand Names
- Monjuvi, Minjuvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1422527-84-1
- Unique Ingredient Identifier
- QQA9MLH692
- Background
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-C...
- Indication
Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).
- Associated Conditions
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05615636
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 20
- Registration Number
- NCT05583071
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Procedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: DoxorubicinDrug: PrednisoneBiological: RetifanlimabBiological: Rituximab and Hyaluronidase HumanBiological: TafasitamabDrug: VincristineProcedure: Bone Marrow AspirationProcedure: Multigated Acquisition ScanOther: Fludeoxyglucose F-18Procedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Biospecimen CollectionDrug: Polatuzumab Vedotin
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 35
- Registration Number
- NCT05455697
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT05453500
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT05429268
- Locations
- 🇧🇬
Medical University Plovdiv, Plovdiv, Bulgaria
🇧🇬Acibadem Cityclinica Mhat Tokuda, Sofia, Bulgaria
🇧🇬Umhat Alexandrovska Sofia, Sofia, Bulgaria
Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT05366218
- Locations
- 🇩🇪
University childrens Hospital, Tübingen, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
🇩🇪Klinik für Kinder- und Jugendmedizin, Ulm, Baden-Württemberg, Germany
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 35
- Registration Number
- NCT05351593
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT05222555
- Locations
- 🇨🇿
Vseobecna Fakultni Nemocnice V Praze, Praha, Czechia
🇨🇿Fakultni nemocnice v Motole, Praha, Czechia
🇨🇿Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT04981795
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.